New York, NY – Nov 14, 2024
Strategic Collaboration Aims to Improve Drug Development Efficiency and Patient Outcomes:
ImmunAI, a pioneering AI-driven biotech company focused on mapping the human immune system, has entered a multi-year collaboration with Teva Pharmaceuticals to advance clinical trial precision in oncology and immunology. This partnership will integrate Immunai’s cutting-edge artificial intelligence technology and immune profiling capabilities to optimize trial design, accelerate drug development, and enhance patient outcomes.
Leveraging AI to Unlock Deeper Clinical Insights
At the core of this collaboration is Immunai’s proprietary AMICA platform—the Annotated Multi-Omic Immune Cell Atlas—recognized as the world’s largest single-cell immune knowledge base. AMICA, powered by tens of millions of immune cells mapped across hundreds of disease settings, integrates insights from over 5,000 studies, including more than 350 single-cell investigations.
This expansive dataset fuels Immunai’s AI-powered Immunodynamics Engine (IDE), which applies functional genomics and machine learning to:
- Enhance biomarker discovery to improve patient stratification
- Optimize dose selection for better efficacy and safety
- Uncover drug mechanisms of action to refine treatment strategies
“Bringing a drug to market is inherently challenging, time-consuming, and costly,” said Noam Solomon, Ph.D., CEO of Immunai. “Through our partnership with Teva, we aim to streamline this process with our AI-driven solutions, empowering clinical teams to make more informed decisions and accelerate the delivery of life-changing therapies.”
Teva Pharmaceuticals to Harness AI for Smarter Trial Design
With a strong commitment to leveraging innovative technologies, Teva Pharmaceuticals will integrate Immunai’s AI and immune profiling expertise into its research and development initiatives. By applying machine learning and advanced computational biology, the collaboration seeks to enhance patient response predictions, refine treatment mechanisms, and improve overall trial success rates.
Eran Harary, Senior Vice President and Global Head of Specialty R&D at Teva Pharmaceuticals, emphasized the potential of AI-driven insights:
“Partnering with Immunai enables us to harness the power of artificial intelligence to gain a deeper understanding of patient responses and disease biology. This collaboration will provide critical data-driven insights to refine our clinical trials and enhance the success of our innovative therapies.”
A Vision for Future Expansion in AI-Powered Drug Development
Looking ahead, the Immunai–Teva partnership may expand to additional areas within Teva’s research and development pipeline, further integrating AI-driven insights into the company’s broader drug development strategy. Both organizations reaffirm their commitment to transforming clinical research through technology, ensuring that novel therapies reach patients with greater speed and precision.
About ImmunAI
ImmunAI is an AI-driven biotech company pioneering the use of immune profiling and machine learning to transform drug discovery and development. Founded in 2018, Immunai integrates advanced computational biology with the world’s largest immune cell database, AMICA, to accelerate precision medicine. With a global presence in New York City, Tel Aviv, Prague, and Zurich, the company is dedicated to unlocking breakthrough therapies in oncology, immunology, and inflammatory diseases.
More about news
By